Division of Nephrology, Ambroise Paré Hospital, APHP, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Boulogne Billancourt/Paris, France; Inserm U-1018, Team 5, Paris-Sud University and Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Villejuif, France.
Inserm U-1018, Team 5, Paris-Sud University and Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Villejuif, France.
Kidney Int. 2016 Jun;89(6):1180-2. doi: 10.1016/j.kint.2016.02.006.
Vascular calcification and kidney fibrosis are 2 important features of chronic kidney disease. Bone morphogenetic proteins/growth differentiation factors and their receptors are implicated in the pathogenesis of both processes. Modulation of the bone morphogenetic protein/growth differentiation factor pathways by a soluble chimeric protein that contains the activin receptor IIA (ActRIIA) domain and acts as an ActRIIA ligand trap for activin and other ligands could become a new therapeutic strategy for vascular calcification and kidney fibrosis in chronic kidney disease.
血管钙化和肾脏纤维化是慢性肾脏病的两个重要特征。骨形态发生蛋白/生长分化因子及其受体参与了这两个过程的发病机制。通过含有激活素受体 IIA（ActRIIA）结构域的可溶性嵌合蛋白来调节骨形态发生蛋白/生长分化因子途径，该蛋白作为激活素和其他配体的 ActRIIA 配体陷阱，可能成为慢性肾脏病中血管钙化和肾脏纤维化的新治疗策略。
